Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
efgartigimod PH20 SC for Pemphigus Vulgaris
Recruiting1 awardPhase 3
Castle Rock, Colorado
This trial is testing a new medication, efgartigimod PH20 SC, to see if it is effective in treating Pemphigus Vulgaris (PV) and Pemphigus Foliaceus (PF), autoimmune diseases that cause blistering of the skin and mucous membranes. The trial will compare efgartigimod PH20 SC to a placebo, and will measure efficacy by looking at patient outcomes.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.